Raptor Pharmaceuticals Announces Phase 2a Clinical Trial Initiation In Non-Alcoholic Steatohepatitis (NASH)
Raptor Pharmaceuticals Corp. (”Raptor” or the “Company”) (OTC Bulletin Board: RPTP), announced the initiation of patient dosing in a Phase 2a clinical trial, in collaboration with the University of California, San Diego (”UCSD”), to evaluate cysteamine bitartrate (”cysteamine”) in adolescents diagnosed with Non-alcoholic Steatohepatitis (”NASH”).
More: continued here
Filed under: GastroIntestinal / Gastroentorology on October 26th, 2008